Semaphorins are a large family of secreted or membrane-associated signaling proteins and Plexins serve as signal transducing Semaphorin receptors^[@R8]--[@R10]^. Sema-Plexin signaling was initially described as mediating growth cone collapse^[@R8],[@R9]^. But, Sema-Plexin signaling is far more diverse^[@R10],[@R11]^. Importantly, Semaphorins and Plexins continue to be expressed in the mature brain where their function remains largely unknown^[@R12]--[@R16]^. Semaphorins, have been documented as synaptic signaling proteins, but this activity has been limited to the control of neuroanatomical synapse formation and elimination^[@R15]--[@R17]^. Here, we demonstrate that Sema-Plexin signaling achieves a retrograde, trans-synaptic control of presynaptic neurotransmitter release and homeostatic plasticity.

We use a well-documented assay to induce PHP, applying a sub-blocking concentration of the glutamate receptor antagonist philanthotoxin-433 (PhTx; 15µM) to significantly decrease average miniature excitatory postsynaptic potential (mEPSP; 0.3 mM \[Ca^2+^\]~e~) or miniature excitatory postsynaptic current (mEPSC; 1.5mM \[Ca^2+^\]~e~) amplitudes. This postsynaptic perturbation induces a significant increase in presynaptic neurotransmitter release (quantal content; QC) that offsets the postsynaptic perturbation and restores normal muscle excitation ([Fig. 1a--c](#F1){ref-type="fig"}: raw values and sample sizes for all normalized data are presented in [Supp Table 1](#SD3){ref-type="supplementary-material"}). This is diagnostic of PHP^[@R1]^. When we repeat this assay in a null mutation of either the *sema2b* gene (*sema2b^C4^*) or the *PlexB* gene (*PlexB^KG00878^*), PHP is blocked ([Fig. 1a--c](#F1){ref-type="fig"}; see also [Extended Data Fig. 1](#F5){ref-type="fig"} for further description of the gene mutations used in this study). Consistent with this being a loss-of-function phenotype, heterozygous mutations (either *sema2b/+* or *PlexB/+*) express normal PHP ([Fig. 1d, e](#F1){ref-type="fig"}). Remarkably, a double heterozygous mutant combination of *sema2b/+* and *PlexB/+* blocks PHP, consistent with both genes acting in concert to drive the expression of PHP ([Fig. 1 d, e](#F1){ref-type="fig"}).

We then explored the long-term maintenance of PHP and the involvement of other *semaphorin* or *Plexin* gene family members. Deletion of a non-essential glutamate receptor subunit (*GluRIIA*) induces a long-lasting form of PHP^[@R1]^. We find that long-term PHP is blocked in a *sema2b, GluRIIA* double mutant as well as in *GluRIIA* animals expressing transgenic RNAi to knockdown *PlexB* selectively in motoneurons ([Fig. 1f, g](#F1){ref-type="fig"}; see also below). Next, we tested mutations in all of the remaining *semaphorin* and *Plexin* genes encoded in the *Drosophila* genome ([Extended Data Fig. 1b](#F5){ref-type="fig"}). The *sema2b* and *PlexB* mutants are the only ones that disrupt PHP.

We, then, performed tissue-specific RNAi and transgenic rescue experiments. Expression of *UAS-Sema2b-RNAi* in motoneurons (*OK371-Gal4*) had no effect on PHP, whereas expression in muscle (*BG57-Gal4*) blocked PHP ([Fig. 2a](#F2){ref-type="fig"}). In addition, expression of *UAS-sema2b* in muscle rescues PHP in the *sema2b* mutant background ([Fig. 2a](#F2){ref-type="fig"}; [Supp Table 1](#SD3){ref-type="supplementary-material"} for additional controls). Consistent with these data, we find that *sema2b* is expressed in muscle and Sema2b protein, expressed under endogenous promoter sequences, concentrates at postsynaptic membranes ([Extended Data Fig. 2](#F6){ref-type="fig"}). Next, we show that motoneuron-specific expression of *UAS-PlexB-RNAi* blocks PHP, whereas muscle-specific expression does not ([Fig 2b](#F2){ref-type="fig"}). We also show that motoneuron-specific expression of a previously characterized *UAS-PlexB^DN^* dominant-negative transgene, lacking the intracellular signaling domain, blocks PHP ([Fig 2b](#F2){ref-type="fig"}). RNAseq analysis of purified MNs demonstrates *PlexB* expression in MNs (data not shown). Finally, motoneuron-specific expression of a *PlexB-myc* transgene shows that PlexB traffics to the presynaptic nerve terminal ([Fig 2d](#F2){ref-type="fig"}). Taken together, our data argue that Sema2b is a ligand originating in muscle that acts via presynaptic PlexB to drive expression of PHP.

If Sema2b is a retrograde signal that acts upon the presynaptic PlexB receptor, then it should be possible to reconstitute this retrograde signaling by acute application of Sema2b protein. Purified Sema2b protein was acutely applied to the *sema2b* mutant NMJ following PhTx treatment to induce PHP. We find that Sema2b protein (\~100nM) completely restores PHP in the *sema2b* mutant, but fails to restore PHP in a *PlexB* mutant ([Fig. 2e--h](#F2){ref-type="fig"}) (see [Extended Data Fig. 3](#F7){ref-type="fig"} for additional controls). In addition, application of Sema2b is sufficient to potentiate baseline release, and this effect is also dependent upon PlexB ([Extended Data Fig 3](#F7){ref-type="fig"}). Finally, a membrane tethered *UAS-sema2b* transgene, expressed in muscle, fails to rescue PHP ([Extended Data Fig. 4](#F8){ref-type="fig"}), even though it concentrates to the postsynaptic membranes ([Fig. 2c](#F2){ref-type="fig"}). Together, these data argue that Sema2b is a secreted postsynaptic ligand that acts upon presynaptic PlexB to enable the expression of PHP. We acknowledge the possibility that PlexB could require a presynaptic co-receptor of, as yet, unknown identity.

Given that acute application of Sema2b rescues PHP in the *sema2b* mutant, the failure of PHP in *sema2b* animals cannot be a secondary consequence of altered NMJ development. None-the-less, Sema2b-Plexin signaling is required for normal NMJ growth. Axon-targeting errors are rare at muscles 6/7, analyzed at the third instar larval stage ([Extended Data Table 1](#T1){ref-type="table"}). We then demonstrate that *sema2b* and *PlexB* NMJ are composed of fewer, larger synaptic boutons ([Fig. 3a--d](#F3){ref-type="fig"}) with no change in total NMJ area ([Fig. 3b](#F3){ref-type="fig"}). The abundance of the active-zone associated protein Bruchpilot (Brp) is unaltered in the *sema2b* mutant and the *sema2b/+;;PlexB/+* double heterozygous animals ([Fig. 3e](#F3){ref-type="fig"}, 'transhet'), both of which block PHP ([Fig. 1a, d, e](#F1){ref-type="fig"}). There is a significant decrease in total Brp staining in *PlexB*, an effect of unknown consequence ([Fig. 3e](#F3){ref-type="fig"}; see also below). Qualitatively, the ring-like organization of Brp staining was similar across all genotypes, indicative of normal active zone organization ([Fig. 3a](#F3){ref-type="fig"} inset, arrows). Finally, there is no consistent difference in synapse ultrastructure across genotypes ([Fig. 3f--i](#F3){ref-type="fig"}). Thus, the Sema2b-PlexinB-dependent control of bouton size may be a separable function of Sema2B-PlexB signaling, analogous to anatomical regulation by semaphorins in mammalian systems^[@R10]--[@R12],[@R15],[@R18]^.

PHP is achieved by potentiation of the readily releasable pool (RRP) of synaptic vesicles^[@R1]^ (see methods). Application of PhTx induces a doubling of the apparent RRP in wild type, an effect that is disrupted in both *sema2b* and *PlexB* mutants ([Fig. 4](#F4){ref-type="fig"}). Failure to potentiate the RRP is also revealed as a failure to maintain the cumulative EPSC amplitude following PhTx application ([Fig. 4c--e](#F4){ref-type="fig"}). We then demonstrate a strong genetic interaction with a mutation in the presynaptic scaffolding gene *rab3 interacting molecule* (*rim*), a presynaptic homeostatic plasticity gene^[@R1]^. Heterozygous mutations in either *rim*, or *sema2b* or *PlexB* have no effect on PHP ([Fig. 4h--i](#F4){ref-type="fig"}). However, double heterozygous combinations of *rim/+* with either *sema2b/+* or *PlexB/+* strongly impaired the expression of PHP (*sema2b/+, rim/+*) or abolished PHP (*rim/+;; PlexB/+*) ([Fig. 4h--i](#F4){ref-type="fig"}). These data do not, however, reflect direct signaling between PlexB and RIM (see also [Extended Data Fig. 3e](#F7){ref-type="fig"}).

To define how PlexB could modulate the RRP, we tested known downstream signaling elements. We discovered that *mical* is necessary for PHP ([Fig. 4](#F4){ref-type="fig"}). In *Drosophila* a single *mical* gene encodes a highly conserved, multi-domain cytoplasmic protein that mediates actin depolymerization, achieved through redox modification of a specific methionine residue (Met44) in actin^[@R7],[@R19]^. Notably, prior genetic evidence has placed Mical downstream of both PlexA and PlexB signaling during axon guidance^[@R20]^.

An analysis of multiple *mical* mutations as well as transgenic rescue animals demonstrates that *mical* is necessary presynaptically for PHP ([Fig. 4a,b,f,g](#F4){ref-type="fig"}). Mical protein is present presynaptically ([Extended Data Fig. 5](#F9){ref-type="fig"}) and presynaptic expression of a Mical-resistant *UAS-Actin5C* transgene^[@R7]^, which interferes with Mical-mediated actin depolymerization, blocks PHP ([Fig. 4a, b](#F4){ref-type="fig"}). This transgenic protein also concentrates within presynaptic boutons ([Extended Data Fig 5](#F9){ref-type="fig"}). Additional experiments reveal that the homeostatic expansion of the RRP is blocked in *mical* and when Mical-resistant *UAS-Act5* is expressed presynaptically ([Fig. 4f,g](#F4){ref-type="fig"}; [Extended Data Fig. 6](#F10){ref-type="fig"}). We find strong genetic interactions between *mical* and both the *PlexB* and *rim* mutants ([Extended Data Fig. 4b--d](#F8){ref-type="fig"}). Finally, anatomical experiments demonstrate that active zones are normal in the *mical* mutant, including both light and electron microscopy ([Fig. 3](#F3){ref-type="fig"}). We propose that Mical connects PlexB to the control of the RRP via regulation of presynaptic actin.

For half a century, evidence has underscored the importance of target-derived, retrograde signaling that controls presynaptic neurotransmitter release^[@R16]^. Gene discovery, based on forward genetics, indicates that PHP is controlled by the coordinated action of at least three parallel signaling systems (see schematic and discussion, [Extended Data Fig. 7](#F11){ref-type="fig"}). If our data regarding Sema2b, PlexinB and Mical can be generalized, then Sema-Plexin signaling could represent a platform for retrograde, trans-synaptic, homeostatic control of presynaptic release, thereby stabilizing synaptic transmission and information transfer throughout the nervous systems of organisms ranging from Drosophila to human.

METHODS {#S1}
=======

Fly Stocks and Genetics {#S2}
-----------------------

In all experiments, the *w^1118^* strain of *Drosophila* melanogaster was used as the wild type control. Male and female animals were used. Animals were maintained at 22°C. When performing rescue, RNAi, or over expression experiments with the *Gal4/UAS* expression system, progeny were raised at 25°C. The following *Drosophila* stocks were used: s*ema-2b*^*C4*\ (21)^, *UAS-sema2b RNAi* (Bloomington stock 28932), *UAS-sema-2b-TM-GFP* ^(21)^, *UAS-sema2b* flies were a gift from Dr. Alex Kolodkin (Johns Hopkins University), *P{GawB}Sema-2b^NP0592^* (Kyoto stock 112237), Sema2b^T:Ivir\\HA1^ (Bloomington stock 65752), *P{SUPor-P}PlexB*^*KG00878*\ (22)^, *UAS-MYC-PlexB*^*EcTM*\ (21)^, *UAS-MYC-PlexB* ^(22)^, *PlexA^EY16548^* (Bloomington stock 23097), *UAS-PlexB-RNAi* ^(18)^, *PlexA^Df(4)C3^* (Bloomington stock 7083), *GluRIIA* ^(23)^, *OK371-Gal4* ^(24)^, *rim*^*103*\ (25)^, *mical*^*K584*\ (6)^, *Df(3R)swp2^mical^ mical* deficiency ^(19)^, *mical*^KG06518\ (6)^, *UAS-mical-RNAi* (Bloomington stock 31148), *UAS-Mical*^*mCherry*\ (26)^, *Mical-GFP Protein Trap* (Bloomington stock number 60203), *UAS-Act5C*^*GFP\ M44L*\ (7)^.

Electrophysiology {#S3}
-----------------

Recordings were made from muscle 6 in abdominal segments 2 and 3 of male and female third-instar larvae in current clamp (0.3mM \[Ca^2+^\]~e~) or voltage clamp (1.5mM \[Ca^2+^\]~e~) as indicated, without randomization^[@R25],[@R27],[@R28]^. Haemolymph-like (HL3) saline was used (70 mM NaCl, 5 mM KCl, 10 mM MgCl~2~, 10 mM NaHCO~3~, 115 mM sucrose, 4.2 mM trehalose, 5 mM HEPES). Quantal content (QC) was calculated by dividing the average EPSP amplitude by the average mEPSP amplitude for each muscle recording (EPSP/ mEPSP) and averages were made across muscles for a given genotype. For acute pharmacological induction of PHP, larvae were incubated in philanthotoxin-433 (PhTx; 10--20 µM; Sigma-Aldrich) for 10 min according to previously published methods^[@R25],[@R27]^. Two-electrode voltage-clamp (TEVC) recordings were done as previously described in 1.5mM \[Ca^2+^\]~e~ HL3 saline^[@R25]^. EPSC analyses were conducted using custom-written routines for Igor Pro 5.0 (Wavemetrics) available as published^[@R29]^, and mEPSPs were analyzed using Mini Analysis 6.0.0.7 (Synaptosoft). Recordings were excluded if the RMP was more depolarized than −60mV. Each experiment was repeated from at least two independent crosses. Key experiments demonstrating a block of synaptic homeostasis were performed blind to genotype by an independent investigator. All controls and experimental genotypes were independently replicated for each experiment in each figure. Experimental sample sizes equal to or greater than 7 were considered sufficiently powered to detect a block in homeostatic plasticity, an effect of size of \~80--120% compared to controls.

Anatomical analyses {#S4}
-------------------

Third-instar larval preparations (muscles 6/7) were filleted and fixed in 4% paraformaldehyde, washed, and incubated overnight at 4°C with primary antibodies. Secondary antibodies were applied at room temperature for 2 hr. The following primary antibodies were used: anti-Myc (9E10 Santa Cruz), anti-GFP 3E6 (1:500; mouse; Life Technologies), anti-NC82 (1:100; mouse; Developmental Studies Hybridoma Bank), anti-HA antibody (1:1000; Rabbit; cell signaling technology) and anti-DLG (1:10,000; rabbit). Alexa-conjugated secondary (488, 555) antibodies and Cy5-conjugated goat ant-HRP were used at 1:500 (Life Technologies; Molecular Probes). Larval preparations were mounted in Vectashield (Vector) and imaged with an Axiovert 200 (Zeiss) inverted microscope, a 100X Plan Apochromat objective (1.4 NA) and a cooled charge-coupled device camera (Coolsnap HQ, Roper). Slidebook 5.0 Intelligent Imaging Innovations (3I) software was used to capture, process and analyze images. Structured illumination microscopy imaging was performed using the N-SIM Nikon system, consisting of a Nikon Ti-E Microscope equipped with a Apo TIRF 100×/1.49 Oil objective and an Andor DU897 Camera.

Sema2b ligand generation and application {#S5}
----------------------------------------

We utilized *Drosophila* S2 expression system to expressed Sema2b AP ligand^[@R21]^ for the bath application of Sema2b ligand to the *Drosophila* NMJ for *in vivo* electrophysiological recordings. Drosophila S2 cells (obtained from the Vale laboratory, UCSF with additional source information at <http://flybase.org/reports/FBtc9000006.html>). Cells are mycoplasma negative, tested by MycoAlert (2017). We co-transfected *UAS-sema2B-AP* and *actin-Gal4* plasmids in S2 Cells using effectene (QIAGEN) and incubate the cells at 27° C for four days in serum free Schneider's media. We then collected the media and diluted the Sema2b-AP ligand in HL3 (0.3 mM Ca^2+^) to 100nM concentration. To record from the NMJ in the presence of bath applied Sema2b AP ligand, we prepared the larval fillet as described above and incubated the prep in Sema2b-AP HL3 for 10 minutes. To assay Sema2b ligand rescue, we bath applied HL3 (0.3 mM Ca^2+^) containing both PhTx (15µM) and Sema2b ligand (100nM) to the preparation for a 10 minute incubation. Next, we removed the PhTx/ Sema2b ligand HL3 saline and replaced it with HL3 containing only 100nM Sema2b ligand to record in the presence of Sema2b.

Transmission Electron Microscopy {#S6}
--------------------------------

Transmission electron microscopy for all third instar larvae were prepared and imaged according to methods previously published^[@R30]^.

Data Availability {#S7}
-----------------

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Extended Data {#S8}
=============

![Mutations in additional *sema* and *Plexin* gene family members do not alter the rapid induction of PHP\
**a)** Gene diagrams indicating the mutations used in this study. Colors match scale bars. **b)** Quantification of the percent change in mEPSP (solid bars) and quantal content (open bars) in the presence of PhTx for the following genotypes: wild type (*w^1118^*), *sema-1a*^k13702^, *sema-1b*^EY21782^, *sema-2a*^EY08184^, *sema-5c*^MI10577^, and *PlexA*^EY1654^. Each was either previously described as, or predicted to be, a strong LOF mutant: *sema-1a*^k13702\ (17)^, *sema-1b*^EY21782\ (31)^, *sema-2a*^EY08184\ (32)^, *sema-5c*^MI10577\ (33)^ and *PlexA*^EY1654\ (31)^. See [supplemental references](#SD1){ref-type="supplementary-material"}. All recordings made at 0.3 mM Ca^2+^.](nihms900687f5){#F5}

![Evidence for *sema2b* gene expression in larval muscle\
**a)** At left, a *sema2b promoter-Gal4* fusion driving *UAS-cd8-GFP* at low magnification to reveal multiple NMJ in the peripheral musculature, all expressing GFP. Muscles 4, 6 and 7 are labeled. Segmental boundaries are indicated by the horizontal lines and the middle segment is indicated as abdominal segment 3 (A3). At right, a higher magnification image taken at muscle 6/7, the muscles at which all recordings are made in this study, revealing expression of *sema2b promoter-Gal4*. The NMJ is labeled with anti-Dlg (pink). Muscle identity is indicated. **b)** Images taken at an identical exposure to those in (a) revealing no background GFP immunofluorescence in the absence of the *UAS-cd8-GFP* reporter as a control. Scale bar left: 200µm, right: 10µm. **c)** Data displayed as in (a). Expression of *sema2b-HA* is controlled by endogenous promoter sequences. Scale bar left: 200µm, right: 10µm. **d)** Structured illumination, super-resolution microscopy (SIM) was used to image Sema2b-HA expressed as in (c). A single optical section (single plane) is shown revealing close proximity between Sema2b (green; anti-HA) and the presynaptic membrane (purple) labeled by anti-HRP. Scale bar 2µm.](nihms900687f6){#F6}

![Effects of exogenous application of Sema2b protein on baseline transmission\
**a)** Raw data and analysis of additional control genotypes for the electrophysiological analysis of the effects of application of exogenous Sema2b protein (0.3 mM \[Ca^2+^\]~e~). **b)** A silver stained protein gel of supernatant collected from S2 cells transfected with both *Actin-Gal4* and *UAS:Sema2b-AP*, or the *Actin-Gal4* plasmid alone (sham). The red box highlights *Sema2b-AP* ligand present at the proper size when both plasmids were transfected together, but absent when *Actin-Gal4* plasmid is transfected alone (Sham lane). Bottom, BSA standards. **c)** Representative traces (0.3mM \[Ca^2+^\]~e~). **d)** Raw data (0.2 mM \[Ca^2+^\]~e~) for indicated genotypes in the absence (filled bars) and following application of exogenous Sema2b protein (open bars; \~100nM protein). Application of Sema2b protein causes a 40% increase in quantal content in controls (n=6) and this effect is blocked in animals that over-express a PlexB dominant negative transgene in motor neurons (OE MN PlexB DN) (control sample size is n=6, and OE MN PlexB DN sample size is n=14). **e)** Effects of applying Sema2b protein to the *rim^103^* mutant (compare *rim Baseline* to *rim + Sema2)*. Experiments performed in 0.4 mM \[Ca^2+^\]~e~ to achieve comparable levels of absolute baseline vesicle release to experiments shown in (a). Sema2b protein has no effect on mEPSP amplitudes, but potentiates both the average EPSP and quantal content in *rim^103^*, demonstrating a significant (p\<0.05) potentiation of release. Sema2b protein rescues the block of PHP observed in the *rim^103^* null mutant. Application of PhTx reduces mEPSP amplitudes in *rim^103^* (p\<0.01) and there no significant increase in quantal content (n.s.) resulting in average EPSP amplitudes being smaller than baseline. When Sema 2b is co-applied with PhTx (*rim* + PhTx + Sema2b), the homeostatic potentiation of quantal content is significantly potentiated (p\<0.01) consistent with a rescue of PHP. *(rim^103^* baseline n=6; *rim^103^* + Sema2b, n=13; *rim^103^* + PhTx, n=7; *rim^103^* + PhTx + Sema2b n=10).](nihms900687f7){#F7}

![Genetic interactions\
**a)** Averaged mEPSP and quantal content in the absence and presence of PhTx for the indicated genotypes. Both genotypes (A and B) expressed the membrane tethered UAS-sema2b-GFP (*UAS-sema2b™-GFP*) in muscle (*BG57-GAL4*). Expression of membrane tethered *UAS-Sema2b-GFP* has no deleterious effects on neurotransmission or the expression of PHP in control animals harboring a heterozygous mutation in the *sema2b* gene (*sema2b/+*) (n=8 minus PhTx and n=8 with PhTx; genotype A). Muscle expression of membrane tethered *UAS-sema2b-GFP* in the *sema2b* homozygous mutant background failed to rescue PHP (n=8, n=9; genotype B). This is in contrast to the observation that expression of wild type *UAS-sema2b* in muscle fully restores PHP in the *sema2b* mutant background (see [Fig. 1](#F1){ref-type="fig"} in main text). We conclude that a membrane tethered Sema2b protein is unable to signal to the presynaptic terminal without being secreted from the postsynaptic membranes. These data are consistent with Sema2b being a secreted ligand, originating in muscle, for the induction and expression of PHP. **b--d)** Averaged mEPSP and quantal content in the absence and presence of PhTx for the indicated genotypes. Heterozygous mutations in *rim/+* (n=8, n=8; minus and plus PhTx respectively), *PlexB/+* (n=9, n=9) and *mical^K584^/+* (n=8, n=8; note *mical^K584^* shortened to *mical^K5^* in figure) express normal PHP following PhTx-dependent inhibition of mEPSP amplitudes. Double heterozygous combinations of *rim/+* with *mical^K584^ /+* (n=9, n=11) or *PlexB/+* with *mical^K584^ /+* (n=8, n=13) results in a complete block of PHP. These genetic interactions indicate that *mical, rim*, and *PlexB* all participate in a common process that is directly required for PHP.](nihms900687f8){#F8}

![Synaptic localization of Mical and Act5C\
**a)** Transgenic expression of *UAS-Act5C^M44L^* (middle; green in merge at right) localizes throughout the presynaptic terminal marked with anti-HRP (left and magenta). Scale bar 5 um. **b)** The transgenic expression of *UAS-mical-mCherry* (green), used to rescue PHP in the *mical* mutant (see main text), localizes to the presynaptic boutons of motor neurons labeled with anti-HRP (magenta). Scale bar 10 um. **c)** Image of a Mical-Protein trap (see methods) reveals endogenous localization of Mical protein in postsynaptic muscle and enrichment at the NMJ labeled by anti-HRP (magenta). Projections in the z-plane (y-z or x-z planes) indicate the presence of Mical protein within the presynaptic bouton of the protein trap. **d)** To selectively image presynaptic Mical-GFP in the protein trap background, *UAS-mical-RNAi* was selectively expressed in muscle (*BG57-GAL4*) in the protein trap-background, greatly reducing muscle Mical-GFP and revealing strong presynaptic Mical-GFP originating from the protein trap at the endogenous gene locus. The NMJ is defined by anti-HRP (magenta, left panel) and by anti-Dlg (magenta, right panel).](nihms900687f9){#F9}

![Representative data showing that homeostatic expansion of the RRP fails in *sema2b, mical* and following expression of mutant *UAS-Act5C*\
Representative traces and graphs indicating cumulative EPSC and back extrapolation from steady state (red line) for the indicated genotypes. **a)** Data are shown for *wild type*. **b)** Data are shown for *sema2b*. **c)** Data are shown for *mical^KG^*. **d)** Data are shown for animals expressing *UAS-DN-Act5C*. We note that *sema2b* mutants have a baseline synaptic transmission defect, with a smaller baseline initial EPSC and correspondingly smaller RRP compared to both wild type and *PlexB* mutants ([Fig. 4](#F4){ref-type="fig"}, main text). Since there is no change in the number of active zone-associated vesicles in *sema2b* mutants ([Fig. 3](#F3){ref-type="fig"}, main text), this defect must reflect a change in the allocation of vesicles to the RRP at baseline that parallels the failure to homeostatically potentiate the RRP during PHP. However, since *PlexB* mutants also block PHP without a change in baseline RRP, it seems unlikely that there is a causal link between reduced baseline RRP and failed PHP in the *sema2b* mutant.](nihms900687f10){#F10}

![A schematic of retrograde, trans-synaptic Sema2b-PlexB signaling\
Signaling is schematized in the context of other mechanisms that have been recently demonstrated to be necessary for presynaptic homeostatic plasticity. Sema2b-PlexB signaling (red shading) is a coherent trans-synaptic, retrograde signaling system that is conveyed, via Mical, to modify presynaptic actin and potentiate the readily releasable synaptic vesicle pool. Other genes have been shown to be necessary for PHP, but none can be connected into a coherent, trans-synaptic signaling cascade. In brown, presynaptic Deg/ENaC channels are inserted into the presynaptic plasma membrane, causing sodium leak and potentiation of presynaptic calcium influx through presynaptic calcium channels (CaV2.1)^[@R35]^. In blue, two components residing in the synaptic extracellular matrix have been implicated in PHP. The α2δ3 auxiliary subunit of the presynaptic calcium channel is necessary for PHP^[@R36]^. The matrix-derived signaling protein Endostatin, a cleavage product of the collagen homologue Multiplexin, is also necessary for PHP^[@R37]^. In orange shading, the innate immune receptor, peptidoglycan recognition protein (PGRP), is essential for PHP^[@R30]^. Signaling downstream of PGRP is hypothesized to reach the neuronal nucleus and could, thereby, mediate the long-term maintenance of PHP. A major task for the future will be to define how these diverse signaling mechanisms participate in a coordinated response that rapidly, accurately and persistently regulates presynaptic neurotransmitter release following disruption of postsynaptic glutamate receptor function.](nihms900687f11){#F11}

###### 

Axon guidance defects for type 1s and type 1b MNs.

  Genotype          1s Guidance defects   1b Guidance defects   n
  ----------------- --------------------- --------------------- ----
  *Sema2b*^4C^      2                     1                     20
  *Sema2b*^4C^/ +   1                     0                     20
  *PlexB*           0                     0                     20
  *PlexB*/ +        0                     0                     20

**Note:** The small number of guidance defects at third instar NMJ may represent the action of compensatory or overlapping mechanisms that promote correct target selection.
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![*Sema2b* and *PlexinB* are necessary for presynaptic homeostatic plasticity\
**a)** Representative traces (left at 0.3mM \[Ca^2+^\]~e~ and right at 1.5mM \[Ca^2+^\]~e~). **b)** Average mEPSP and quantal content (QC) expressed as a percent change in the presence of PhTx compared to each genotype in the absence of PhTx. **c)** Data as in (b) at 1.5mM \[Ca^2+^\]~e~. **d)** Representative traces as in (a). **e)** Average data as in (b). **f)** Representative traces as in (a) for indicated genotypes alone (*GluRIIA^+/+^*) or as double mutants with *GluRIIA* (*GluRIIA^−/−^*). **g)** Average data for each genotype compared to the genotypic control in the absence of the *GluRIIA* mutation. \*\* p\<0.01 student's t-test (2-tail), pairwise comparison to genotypic control. Data are mean ± standard error. Individual data points are overlaid.](nihms900687f1){#F1}

![Sema2b and PlexinB function as a retrograde trans-synaptic signal\
**a)** Representative traces (0.3 mM \[Ca^2+^\]~e~). Quantification of mEPSP and QC as in [Fig.1b](#F1){ref-type="fig"}. 'Muscle Gal4' is *BG57-Gal4/+*. 'MN-Gal4' is *OK371-Gal4/+*. 'MN *sema2b* RNAi' is *Ok371-Gal4/+*; *UAS-sema2b-RNAi/+*. 'Muscle *sema2b* RNAi' is *BG57-Gal4/+, UAS-sema2b-RNAi/+*. 'Muscle sema2b rescue' is *sema2b*; *BG57-Gal4/ UAS-sema2b*. **b)** Traces, data graphed as in (a). 'MN *PlexB* RNAi' is *Ok371-Gal4/+*; *UAS-PlexB-RNAi/+*. 'MN DN PlexB' is *Ok371-Gal4/+* expressing *UAS-PlexB-DN*. 'Muscle PlexB RNAi' is *BG57-Gal4/+, UAS-PlexB-RNAi/+*. **c)** Muscle-specific expression (*BG57-Gal4/+*) of a *UAS-Sema2b-CD8-GFP*. Anti-HRP (blue) labels neuronal membrane. Anti-Dlg (pink) labels postsynaptic membranes. **d)** *UAS-PlexB-GFP* (green) expressed in motoneurons (*OK371-Gal4/+*). **e)** Traces for *sema2b* mutant in the absence (baseline) and presence of PhTx. 'Sham' is incubation in saline lacking Sema2b. The "+Sema2b" indicates addition of Sema2b (100nM). **f)** Traces as in (e) for *PlexB* mutant. **g)** Quantification for conditions in (e). **h)** Quantification of data in (f). Significance \*\* = p\<0.01; Student's t-test (2-tail), pairwise to genotypic control (a and b), pairwise comparison to wild type (g and h). Data are mean ± standard error; data points are overlaid.](nihms900687f2){#F2}

![Altered NMJ growth with normal active zone number and integrity\
**a)** Structured illumination microscopy (SIM) images of NMJ. Inset: single confocal sections, arrows indicate Brp rings. Scale 5µm. Inset scale 0.5µm. **b--e)** Quantification of morphology; n=12 except *Mical^KG^* n=10. **f)** Representative active zones. Scale = 70nm. **g--i)** Quantification of ultrastructure. \* = p\<0.05, \*\* = p\<0.01 Student's t-test (2-tail), pairwise comparison to *wild type*. 2 animals per genotype; wt n=16 active zones (AZ), *sema2b* n=29 AZ, *PlexB* n=30 AZ and *Mical* n=13 AZ. Data are mean ± standard error; data points are overlaid.](nihms900687f3){#F3}

![Sema2b, PlexinB and Mical control the homeostatic potentiation of the RRP\
**a)** The *mical* mutants (green) at 0.3 (left) and 1.5 (right) \[Ca^2+^\]~e~ and Mical-resistant *UAS-Act5C* transgene (red) block PHP. **b)** Expression of *UAS-mical* in motoneurons (MN Mical Rescue) rescues PHP. *mical* RNAi from MNs blocks PHP. *mical* RNAi in muscle is without effect (right). **c)** Traces from wild type (black) and *PlexB* (blue) (1.5 mM \[Ca^2+^\]~e~) +/− PhTx (stimulation frequency 60Hz, 30 stimuli). Cumulative EPSC and back extrapolation from steady state (red line) is shown below each trace. **d)** Quantification of the % change in RRP (open) and mEPSP (filled) in the presence of PhTx compared to baseline for each genotype in the absence of PhTx. Sample size: wt (−PhTx)=14, (+PhTx)=9; *sema2b* (−PhTx)=9, (+PhTx)=9; *PlexB* (−PhTx)=10, (−PhTx)=11. **e)** Quantification of cumulative EPSC for recordings in (d). Primary data (red circles). **f)** Quantification as in (e) for wild type (-PhTx)=6, (+PhTx)=6, the *mical* mutant (−PhTx)=12 (+PhTx)=11 and in animals overexpressing dominant negative *Act5C* (−PhTx)=8 (+PhTx)=8. **g)** Quantification of cumulative EPSC. **h)** Representative traces. **i)** Genetic interactions of *sema2b*/+ or *PlexB/+* with the *rim/+.* Significance \* = p\<0.05; \*\* = p\<0.01. Data are mean ± standard error; data points are overlaid.](nihms900687f4){#F4}
